Espram

Quick links to important sections

Espram

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Espram

Here is a quick facts overview of the combination medicine Espram, which contains the active ingredients Escitalopram and Esomeprazole:

Property Description
Active ingredient Escitalopram and Esomeprazole
Form Oral tablets
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI) and Proton Pump Inhibitor (PPI) combination
Origin Synthetic compound
General Type Fixed-dose combination (FDC), Prescription-only

What is Espram and What is it Made Of?

Espram is a prescription-only fixed-dose combination product supplied as oral tablets, which contains two different active pharmaceutical ingredients (INN) in a single unit. The composition involves two synthetic compound agents: Escitalopram and Esomeprazole. Escitalopram is identified as the S-enantiomer of citalopram, while Esomeprazole is recognized as the S-isomer of omeprazole. This specific formulation is distinguished by its precise, fixed ratio of the active agents, offering a single administration point for the two therapies rather than requiring separate tablets.

Dual-Action: The Class of Espram

This medication is uniquely classified as a dual-action therapeutic combination because its components belong to two entirely different, high-level pharmacological categories. The first component, Escitalopram, is classified as a Selective Serotonin Reuptake Inhibitor (SSRI), a type of psychotropic antidepressant. The second component, Esomeprazole, is classified as a Proton Pump Inhibitor (PPI), which functions by inhibiting gastric acid secretion. The strategy of combining an SSRI and a PPI is intended for use in psychiatric patients with co-existing upper gastrointestinal symptoms.

Why Combine Mood and Gastric Agents?

The overarching therapeutic purpose of combining Escitalopram and Esomeprazole is to facilitate streamlined management for adult patients who experience co-morbid psychiatric and gastrointestinal conditions. This approach acknowledges the established physiological connection between the central nervous system and digestive health. The formulation is intended to provide a unified strategy by influencing mood regulation and, at the same time, protecting the digestive system from the effects of excess acid. This combined action relates to the potential for therapeutic synergy in addressing depression with concurrent acid peptic disorders.

Regulatory References

  1. NIH: Combination Therapy for Depression

What side effects are possible with Espram?

Possible side effects and safety information

The official safety profile for Espram, a fixed-dose combination, reflects the documented adverse reactions of its two components, Escitalopram (SSRI) and Esomeprazole (PPI), as classified by regulatory authorities.

Adverse reactions are classified by frequency and system-organ class:

Classification Key Adverse Reactions (System-Organ Class)
Very Common Headache (Nervous System), Nausea (Gastrointestinal), Ejaculation Disorder (Reproductive System)
Common Insomnia, Somnolence (Nervous System), Diarrhea, Constipation, Dry Mouth (Gastrointestinal), Increased Sweating (Skin), Fatigue (General)

Serious and systemic safety concerns are documented in the prescribing information, including a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in young adults (up to age 24) when treated with SSRIs, particularly at the start of therapy. Serious reactions include Serotonin Syndrome, which is a risk when combining with other serotonergic agents, and the potential for QT Interval Prolongation, which may lead to severe cardiac events. The label specifies that this medicine is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) and Pimozide.

Safety notes tied to duration or specific populations are also included. Long-term exposure to the PPI component is associated with risks of bone fractures of the hip, wrist, or spine, and Hypomagnesemia (low magnesium levels). Older adults have a documented increased risk for conditions like Hyponatremia (low sodium levels in the blood) and require particular caution. Patients with severe hepatic impairment are typically advised against use.

Overdose and Emergency Response

The official regulatory profile for an Espram overdose focuses on the documented toxicities of the Escitalopram component, particularly the potential for severe central nervous system and cardiac events. Overdose manifestations officially listed include central nervous system effects such as dizziness, somnolence, convulsions, and coma, alongside gastrointestinal symptoms like nausea and vomiting. Cardiovascular effects documented in overdose are QTc prolongation, sinus tachycardia, and hypotension. The primary life-threatening outcomes listed in regulatory documents include the potential for Serotonin Syndrome and ventricular arrhythmias, such as Torsade de Pointes. This risk is amplified when the medication is co-ingested with other substances. Given the potential for serious cardiac or neurological events, any suspected overdose requires immediate medical attention. Official management is symptomatic and supportive treatment. Continuous ECG monitoring is required due to the risk of QTc changes. It is officially stated that no specific antidote is known for the active components. Specific populations, such as those with existing cardiac disease or hepatic impairment, may be at an increased risk of severe outcomes.

Therapeutic Uses of Espram

Main Uses and Therapeutic Intent

Espram is a medication primarily indicated for the treatment of various mental health conditions characterized by disruptions in mood and anxiety levels. It belongs to the class of drugs known as selective serotonin reuptake inhibitors (SSRIs). The medication is most frequently utilized to address symptoms associated with clinical depression and several distinct anxiety-related disorders.

Major Depressive Disorder

The primary application of Espram is the management of major depressive episodes. In this context, the medication aims to alleviate the persistent feelings of sadness, loss of interest in daily activities, and the physical fatigue often associated with depression. By influencing chemical signaling in the brain, it helps in stabilizing mood and improving the patient's overall sense of well-being.

Anxiety Disorders

Espram is also indicated for several types of chronic anxiety. These conditions involve more than temporary stress and are often characterized by persistent, excessive worry that interferes with daily functioning:

  • Generalized Anxiety Disorder (GAD): Treatment focuses on reducing the constant, low-level anxiety and tension regarding everyday life events.
  • Social Anxiety Disorder: The medication is used to help patients manage the intense fear of social situations or performance-related environments.
  • Panic Disorder: It is utilized to decrease the frequency and intensity of panic attacks, as well as the anticipatory anxiety related to having future attacks.
  • Obsessive-Compulsive Disorder (OCD): In some clinical contexts, it is used to help manage the repetitive thoughts and behaviors associated with this condition.

Potential Benefits and Clinical Goals

The goal of treatment with Espram is the gradual improvement of psychological symptoms over time. While individual responses vary, the intended benefits typically include:

  • Mood Stabilization: Helping to return the patient to a more balanced emotional baseline.
  • Improved Cognitive Focus: As depressive symptoms lift, many patients experience a restoration of concentration and mental clarity.
  • Physical Symptom Relief: Improving sleep patterns and energy levels that are often disrupted by mood disorders.
  • Reduction in Avoidance Behavior: By lowering anxiety levels, the medication may help individuals re-engage with social or professional activities they had previously avoided.

Eligibility and Restrictions for Use

Espram, which contains the active ingredient escitalopram, is approved for use in adults and adolescents aged 12 years and older to treat Major Depressive Disorder (MDD). For Generalized Anxiety Disorder (GAD), its use is generally approved for adults.

Contraindications and Warnings

Certain conditions or concomitant medications make the use of Espram potentially unsafe. It is contraindicated (should not be used) in patients:

  • Who are taking or have recently stopped taking (within 14 days) a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue, due to the risk of Serotonin Syndrome.
  • Who are taking the antipsychotic medication pimozide.
  • With a known hypersensitivity or allergy to escitalopram, citalopram, or any component of the formulation.

Specific Patient Populations

Caution is generally advised when prescribing Espram to individuals with the following health issues, as the benefits must be carefully weighed against the risks:

Population/Condition Cautionary Note
Pediatrics (under 12) Safety and efficacy are not established.
Elderly patients May be more susceptible to side effects like low sodium (hyponatremia).
Seizure history May increase seizure risk; use with care.
Bipolar Disorder Can trigger manic episodes.
Severe Renal/Liver Disease Dosage adjustment may be necessary.
Heart conditions Risk of QT interval prolongation, a serious heart rhythm issue.
Bleeding disorders May increase risk of abnormal bleeding.
Narrow-angle Glaucoma Risk of developing or worsening angle-closure glaucoma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies multiple clinically significant interactions for Espram (escitalopram).

Contraindicated Combinations

Classification Interacting Agents Rationale
Serotonergic Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue Risk of Serotonin Syndrome. A 14-day washout period is required when switching between these agents.
Pharmacodynamic Pimozide Risk of QTc interval prolongation, which can cause serious heart rhythm abnormalities.

Use with Caution and Monitoring

  • Serotonergic Drugs: Co-administration with other serotonergic agents (e.g., triptans, tramadol, tricyclic antidepressants, St. John's Wort) increases the risk of Serotonin Syndrome. Close observation is required, particularly at the start of treatment and following dose changes.
  • Drugs Affecting Hemostasis: Concomitant use with anticoagulants (e.g., Warfarin) or antiplatelet agents (e.g., NSAIDs, Aspirin) increases the risk of bleeding due to Escitalopram's effect on platelet function.
  • Enzyme Interaction (CYP2D6): Escitalopram is a documented weak inhibitor of the CYP2D6 enzyme. This can lead to increased exposure of co-administered medicines that are primarily metabolized by this enzyme (e.g., certain antipsychotics or tricyclic antidepressants).
  • Enzyme Interaction (CYP2C19): Concomitant use with strong inhibitors of the CYP2C19 enzyme (e.g., Omeprazole, Cimetidine) can moderately increase Escitalopram plasma concentrations.

Mechanism of Action

Targeted Serotonin Signaling Modulation

This domain centers on Espram’s selective action to inhibit the serotonin transporter (SERT), a mechanism that acts within domains involving receptor- or enzyme-mediated signaling. This process modifies early molecular steps by preventing serotonin reuptake, which directly increases the concentration of the neurotransmitter in the synaptic cleft, resulting in an elevated concentration of the neurotransmitter available for receptor binding.

Altering Downstream Receptor Activity

The sustained increase in available serotonin initiates signaling sequences that lead to altered post-synaptic receptor activation and subsequent cellular changes. This action modulates key pathways by influencing long-term cellular response and engaging mechanisms that influence feedback regulation within the affected neural pathways.

Influence on Neural Homeostatic Mechanisms

By influencing these specific transmitters or mediators, the drug engages mechanisms that regulate overactive or dysregulated processes in the systems where they dominate. This activity decreases the extent of elevated mediator activity and establishes altered signaling parameters within targeted pathways, resulting in altered dynamics within the affected neural circuits.

Dosage and Administration Information

How to Use Espram: Official Administration Guidelines

This section describes the official instructions for the fixed-dose combination product Espram (Escitalopram and Esomeprazole).


Administration Scope

Usage Entity Official Regulatory Principle
Route of Administration The sole approved route for this combination is oral via tablets.
Standard Dosing Treatment typically involves once-daily dosing. The Escitalopram component is often initiated at 10 mg once daily, with a maximum dose of 20 mg per day in most adults.
Meal Timing The tablet must be taken at least one hour before meals.
Preparation The tablet must be swallowed whole with fluid and should not be crushed, chewed, or cut to protect the delayed-release formulation of the Esomeprazole component.
Dose Titration Any increase in the Escitalopram component's dosage requires a minimum interval of one week between adjustments.

Population and Procedural Rules

  • Older Adults (Geriatric): The typical dose for the Escitalopram component is generally limited to 10 mg once daily.
  • Hepatic Impairment: Patients with severe hepatic impairment are restricted to a maximum daily dose of 20 mg for the Esomeprazole component.
  • Discontinuation: Cessation of therapy requires a gradual dose reduction (tapering) of the Escitalopram component to minimize the risk of procedural symptoms.

Connection to the Overall Use Protocol

The official instructions establish a structured once-daily oral regimen. This protocol is defined by the necessity of taking the tablet before food and maintaining its physical integrity by swallowing it whole. These procedural constraints and the specific dose limits for vulnerable populations are central to the administration of the combination product.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Espram

This overview summarizes the formal clinical research and study types that have been conducted for the two main components of Espram, drawing from regulatory sources and peer-reviewed scientific literature. The text describes what research examined and what patterns were reported, without offering any clinical advice or individual prediction.


Evidence for Management of Major Depressive and Anxiety Symptoms (Escitalopram Component)

The clinical evaluation for the psychiatric component involved numerous short-term Randomized Controlled Trials (RCTs). These studies explored how symptoms change over time in adult outpatients with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Researchers monitored outcomes related to systemic or functional imbalance by measuring shifts in symptom intensity using standardized psychiatric scales over defined time intervals. Findings describe patterns observed in the studies related to measured changes in mood and functional imbalance.


Evidence for Management of Acid-Related Gastrointestinal Discomfort (Esomeprazole Component)

The evaluation of the gastrointestinal component involved Randomized Controlled Trials and systematic reviews. The research examined outcomes linked to inflammatory or irritative states, focusing on conditions associated with acute or disruptive episodes, such as Erosive Esophagitis. Randomized Controlled Trials explored outcomes linked to inflammatory or irritative states by measuring changes in the esophageal lining over short-term assessment periods. Findings describe patterns observed in the studies related to the resolution of tissue damage and patient-reported outcomes describing perceived discomfort for the single-agent GI component.


Studies on the Fixed-Dose Combination and Co-Administration

The research base for the specific fixed-dose combination product is structured differently, focusing on Pharmacokinetic (PK) Studies and Bioequivalence Studies. These studies monitored the blood concentration levels of the active ingredients when taken together. Research examined how one component (Esomeprazole) was associated with changes in the measured concentration of the other component (Escitalopram). Data show patterns related to drug absorption and metabolism, which provided context for regulatory review.

Comparative evidence is lacking regarding the clinical outcomes of patients taking the fixed-dose combination versus those taking the two components as separate tablets. Furthermore, long-term effects are not fully established for the fixed-dose combination, and there is limited information for long-term outcomes extending beyond the typical maintenance phase of the individual psychiatric component.

Key Studies & References Study Details: Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders (NCT03122158) (Adolescent/Variable Outcomes)

Frequently Asked Questions (FAQ)

Common questions about Espram (FAQ)


Q: Can Espram cause strange dreams or sleep disturbances?

Yes, official product information for the Escitalopram component indicates that sleep disturbances and abnormal dreaming have been reported. Insomnia (difficulty sleeping) and somnolence (sleepiness) are also listed among common adverse reactions.


Q: Is Espram a good choice for anxiety, or is it just for depression?

According to the official regulatory documents, the Escitalopram component of Espram is indicated for the treatment of both Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) in adults. This means it is approved for the treatment of these two specific conditions.


Q: Do you have to take Espram forever?

Official labeling for the Escitalopram component addresses the use for both acute treatment and maintenance treatment of Major Depressive Disorder. The duration of treatment, including whether maintenance therapy is appropriate, is determined by the prescribing healthcare provider based on the patient's condition.


Q: How does Espram interact with alcohol?

Although clinical studies have not shown that Escitalopram increases the mental and motor skill impairment caused by alcohol, the concomitant use of Escitalopram and alcohol in depressed patients is not advised according to the product label.


Q: Why is it important to check interactions with other medications before starting Espram?

Checking for potential interactions is important because the medicine can increase the risk of serious conditions like Serotonin Syndrome (with other serotonergic drugs) and bleeding (with anticoagulants), as detailed in the official safety warnings.


Q: Is Espram considered a 'habit-forming' drug?

The Escitalopram component is not classified as a controlled substance by the DEA and does not have abuse potential. However, stopping treatment requires gradual dose reduction to minimize discontinuation symptoms.


Q: What's the difference between Espram and other SSRIs?

The key difference is that Espram is a fixed-dose combination product. It contains two active ingredients: Escitalopram (an SSRI for mood) AND Esomeprazole (a PPI for acid reduction) in a single tablet. Most other SSRIs contain only the single antidepressant ingredient.


Q: Is there a specific time of day that is best for taking Espram?

The Escitalopram component can generally be administered once daily, either in the morning or the evening. However, the tablet must also be taken at least one hour before a meal. Consult the prescribing information or a healthcare provider for the specific administration schedule.


Q: What kind of research has been done on the long-term effects of Espram?

Research on the specific fixed-dose combination product focused on Pharmacokinetic (PK) studies, which monitored drug concentration. Separately, the long-term use of the PPI component is associated with warnings regarding risks like bone fractures and hypomagnesemia (low magnesium levels).


Q: How does Espram target serotonin in the brain?

The Escitalopram component's mechanism of action involves selectively inhibiting the reuptake of serotonin (5-HT) in the brain. By blocking this reabsorption, the concentration of the neurotransmitter serotonin increases in the synaptic cleft.


Q: Can Espram make it difficult to concentrate?

The medicine can cause side effects like somnolence (sleepiness), and the label includes a general warning regarding its potential to impair judgment, thinking, and motor skills.


Q: Can Espram be taken during pregnancy?

Neonates exposed to SSRIs late in the third trimester have uncommonly been reported to have clinical findings consistent with either a direct drug effect or a drug discontinuation syndrome. The decision regarding use during pregnancy must be made after careful consideration of potential risks and benefits.


Q: What is the role of Espram in managing generalized anxiety disorder (GAD)?

The Escitalopram component is officially indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults. This means it has received regulatory approval specifically for the treatment of GAD.


Q: Can Espram cause night sweats?

Yes, the official adverse reaction profile for the Escitalopram component lists increased sweating as a common side effect. Increased sweating may sometimes be experienced as night sweats.


Q: How quickly does Espram usually start to make a difference?

Official regulatory documents confirm that clinical trials focused on monitoring symptom changes over time, but they do not specify a fixed timeframe for when therapeutic effect may be noted. Response time varies among individuals.


Q: Does Espram affect energy levels or cause fatigue?

Official information lists both fatigue and somnolence (sleepiness) as common adverse reactions for the Escitalopram component. The regulatory documentation focuses on reporting adverse events and does not provide claims regarding increased energy levels.


Q: Is it normal to feel a little worse when first starting Espram?

The official label contains a Boxed Warning that notes an increased risk of suicidal thoughts and behaviors in young adults, particularly at the beginning of therapy. This information highlights the need for careful observation during the initial treatment period.


Q: Can you drink coffee while taking Espram?

The regulatory interaction section does not specifically mention coffee or caffeine. However, the tablet must be taken at least one hour before a meal due to the administration requirements of the medication.


Q: What are some signs that Espram might not be working for someone?

Clinical research evidence describes how effectiveness was measured using standardized psychiatric rating scales. The product label does not define specific patient-observable signs of non-response, which would require professional assessment.


Q: Does Espram affect blood pressure or heart rate?

The official safety documentation highlights the risk of QT interval prolongation, a serious cardiac event. While the official profile addresses this heart rhythm issue, it does not list general changes to typical blood pressure or resting heart rate as common side effects.


Q: Are there any vitamins or supplements that should not be combined with Espram?

Yes, the official interaction warnings note that co-administration with other serotonergic agents should be done with caution. St. John's Wort is highlighted as a supplement that should be used with caution due to the potential increased risk of Serotonin Syndrome.


Q: What are the common withdrawal symptoms people report when stopping Espram?

The official instructions emphasize that cessation requires a gradual dose reduction (tapering) to minimize the risk of procedural symptoms. While the core label confirms the need for tapering, it does not detail a specific list of what those symptoms typically are.


Q: Are there special considerations for people with liver or kidney issues taking Espram?

Yes, regulatory information advises specific cautionary notes. For instance, a reduced maximum dose is required for the Escitalopram component in patients with severe hepatic (liver) impairment, and dosage adjustment may be necessary for those with severe renal or liver disease.


Q: How do people manage nausea when starting Espram?

Nausea is listed in the official profile as a very common adverse reaction, especially when starting the treatment. While the label confirms the symptom, it does not provide specific coping strategies. Coping strategies for managing this symptom are typically discussed by a healthcare provider.


Q: What does the research say about Espram's effectiveness compared to placebo?

Clinical evaluation for the Escitalopram component involved numerous short-term Randomized Controlled Trials (RCTs). These studies were designed to compare outcomes against a control group (placebo) to establish the drug's effectiveness in its indicated conditions.


Q: Does taking Espram affect driving ability?

Official warnings caution that the medicine can cause side effects like somnolence (sleepiness) and may impair judgment, thinking, and motor skills. The potential to impair judgment, thinking, and motor skills means caution should be exercised when engaging in activities that require mental alertness, such as driving or operating heavy machinery.


Q: Does food affect the absorption of Espram?

Yes, official administration guidelines require the tablet to be taken at least one hour before a meal. This constraint is necessary because the presence of food can impact the drug's formulation and function, based on the administration requirements of the Esomeprazole component.


Q: Does Espram impact sexual function?

Yes, official safety information indicates that ejaculation disorder is a very common adverse reaction associated with the Escitalopram component. The official profile focuses on ejaculation disorder, but sexual side effects are generally associated with this class of medication.


Q: Is Espram safe for older adults?

Official warnings indicate that older adults may require particular caution. They may be more susceptible to certain side effects, such as hyponatremia (low sodium levels in the blood), and the maximum recommended dose for the Escitalopram component is often lower.

How should Espram be stored and disposed of?

How to Store and Dispose of Espram?

Espram (Escitalopram/Esomeprazole) tablets require specific handling to maintain stability, as dictated by official regulatory standards.


Storage Requirements

The medication must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from light and moisture, and it is required to keep the container tightly closed and in its original packaging. Do not freeze the tablets. Always store Espram out of the sight and reach of children.


️ Disposal Instructions

Expired or unused Espram should be disposed of according to the official protocol. The preferred method is to utilize a drug take-back program. If this is unavailable, the tablets should be mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container before placing in the household trash. Do not dispose of the medication by flushing it down the toilet or pouring it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Espram found in:

A-Z Index: